LINC-ROR and psoriasis: Currently, novel RORγt inhibitors are monitored in the clinical studies: ABBV-157 in psoriasis phase I (NCT03922607); JTE-451 and ESR-114 in psoriasis phase II (NCT03832738 and NCT03630939, respectively); ARN-6039 in MS phase I (NCT03237832); AUR-101 in psoriasis phase II (NCT04207801); RTA-1701 in healthy phase I (NCT03579030); GSK2981278 in psoriasis phase I (NCT03004846 and NCT02548052); SAR-441169 in psoriasis phase I; and ROR antagonists in inflammatory disease phase I (100) (Table 1).